Transcultural adaptation of the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) into Brazilian Portuguese by Serrano, Erica Vieira et al.
www.reumatologia.com.br
REVISTA BRASILEIRA DE
REUMATOLOGIA
R E V  B R A S  R E U M A T O L .  2 0 1 3 ; 5 3 ( 6 ) : 4 8 3 – 4 9 3
* Corresponding author.
E-mail: val.valim@gmail.com (V. Valim).
0482-5004/$ - see front matter. © 2013 Elsevier Editora Ltda. All rights reserved. http://dx.doi.org/10.1016/j.rbre.2013.04.003
Original article 
Transcultural adaptation of the “EULAR Sjögren’s Syndrome 
Disease Activity Index (ESSDAI)” into Brazilian Portuguese 
Érica Vieira Serranoa,b,c, Valéria Valimd,e,f,*, Samira Tatiyama Miyamotod,g, 
Raquel Altoé Giovellib,h, Maurício Aquino Paganotti i, Nágela Valadão Cadê j,k,l
a Post-graduation Program in Collective Health, Universidade Federal do Espírito Santo, Vitória, ES, Brazil 
b Department of Internal Medicine, Escola Superior de Ciências, Santa Casa de Misericórdia de Vitória, Vitória, ES, Brazil 
c Hospital Universitário Cassiano Antônio de Moraes, Vitória, ES, Brazil 
d Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
e Department of Internal Medicine, Universidade Federal do Espírito Santo, Vitória, ES, Brazil
f Rheumatology Outpatient Clinic, Hospital Universitário Cassiano Antônio de Moraes, Vitória, ES, Brazil 
g Discipline of Physical Therapy, Universidade Federal do Espírito Santo, Vitória, ES, Brazil 
h Master’s Degree Program in Medicine, Universidade Federal do Espírito Santo, Vitória, ES, Brazil
i Post-graduation Program in Pharmaceutical Sciences, Universidade de Vila Velha, Vila Velha, ES, Brazil
j Post-graduation Program in Nursing, Universidade de São Paulo, São Paulo, SP, Brazil
k Discipline of Nursing, Universidade Federal do Espírito Santo, Vitória, ES, Brazil
l Post-graduation Program in Collective Health, Universidade Federal do Espírito Santo, Vitória, ES, Brazil
a r t i c l e  i n f o
Article history:
Received 5 December 2012
Accepted 23 April 2013
Keywords:
Sjögren’s syndrome
Scales
Validation studies
ESSDAI
a b s t r a c t
Introduction: The EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) is an index of 
primary Sjögren’s syndrome (PSS) systemic activity. 
Objective: To perform the ESSDAI transcultural adaptation into Brazilian Portuguese.
Method: This was a cross-sectional study with 62 patients with PSS according to the criteria 
of the 2002 American-European Consensus. Six stages were conducted: conceptual, item, 
semantic, operational, functional, and measurement equivalences (interobserver repro-
ducibility and construct validity). For the validity assessment, the ESSDAI was compared 
with the Physician’s Global Assessment (PhGA), the Sjögren’s Syndrome Disease Activity 
Index (SSDAI), and the Sjögren’s Systemic Clinical Activity Index (SCAI). Patients were clas-
sifi ed by a specialist physician into two groups according to disease activity (active and 
inactive), and according to the intention-to-treat (increase in therapy and no increase in 
therapy). The ESSDAI was tested in these groups. The following statistical tests were used: 
intraclass correlation coeffi cient (ICC), Bland-Altman plot for reproducibility, and Spear-
man’s correlation coeffi cient (rs) and Mann-Whitney’s test for validity (P < 0.05 and 95% CI).
Results: The mean ESSDAI score was 4.95 ± 6.73. The reproducibility obtained a strong ICC 
of 0.89 and good agreement. When compared with other indices, it showed a strong rs with 
PhGA (0.83; P < 0.000), a moderate rs with SSDAI (0.658; P < 0.000) and a weak rs with the 
SCAI (0.411; P = 0.001). The group “active” and the group “ increase in therapy” had higher 
ESSDAI values  (P = 0.000).
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Adaptação transcultural do “EULAR Sjögren’s Syndrome Disease Activity 
Index (ESSDAI)” para a língua portuguesa
Palavras-chave:
Síndrome de Sjögren
Escalas
Estudos de validação
ESSDAI
r e s u m o
Introdução: O EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) é um índice de 
atividade sistêmica da síndrome de Sjögren primária (SSP).
Objetivo: Realizar a adaptação transcultural do ESSDAI para a língua portuguesa.
Método: Estudo transversal com 62 pacientes com SSP de acordo com consenso europeu-
-americano de 2002. Foram realizadas seis etapas: equivalência conceitual, de item, se-
mântica, operacional, funcional e de mensuração (reprodutibilidade interobservador e a 
validade de constructo). Para a validade, o ESSDAI foi comparado com a avaliação global do 
médico (PhGA), o Sjögren’s Syndrome Disease Activity Index (SSDAI) e o Sjögren’s Systemic 
Clinical Activity Index (SCAI). Os pacientes foram classifi cados por um médico especialista 
conforme a atividade da doença em dois grupos, “ativo” e “inativo”, e conforme a intenção 
de tratar nos grupos “aumento de terapia” e “sem aumento de terapia”. O ESSDAI foi tes-
tado nesses grupos. Utilizou-se os testes estatísticos: coefi ciente de correlação intraclasse 
(CCI) e método de Bland Altman para a reprodutibilidade; e coefi ciente de Spearman (rs) e 
teste de Mann-Whitney para a validade (P < 0,05 e IC 95%).
Resultados: A média do ESSDAI foi de 4,95 ± 6,73. A reprodutibilidade obteve um forte CCI de 
0,89 e boa concordância. Na comparação com outros índices, apresentou forte coeficiente 
de Spearman com o PhGA (rs = 0,83; P < 0,000), moderado com o SSDAI (rs = 0,658 ; P < 0,000) 
e fraco com o SCAI (rs = 0,411; P = 0,001). O grupo “ativo” e o grupo “com aumento de terapia” 
obtiveram maiores valores de ESSDAI (P = 0,000).
Conclusão: a versão em português do ESSDAI mostrou ser adaptável, reprodutível e válida 
para a língua portuguesa.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Conclusion: The Brazilian Portuguese version of ESSDAI was shown to be adaptable, repro-
ducible, and valid for this language.
© 2013 Elsevier Editora Ltda. All rights reserved.
Introduction
Primary Sjögren’s syndrome (PSS) is the second most com-
mon autoimmune rheumatic disease,1 after rheumatoid ar-
thritis, with an estimated prevalence in the Brazilian popula-
tion of 0.17%.2 However, due to the scarcity of studies focused 
on the treatment of its systemic manifestations, PSS still has 
treatment directed to its dryness manifestations. This limita-
tion arises from the lack of appropriate tools to assess the 
systemic activity of PSS. 3,4 Moreover, the few studies pub-
lished on PSS used different methods to measure the same 
parameter, creating a heterogeneous fi eld of results within 
the same subject, which prevents the progress of research in 
the construction of knowledge.5 Therefore, validated tools as-
sessing PSS activity are necessary6,7 to evaluate the effective-
ness of new therapies that focus both on severe systemic 8-12 
and glandular 8,13,14 manifestations. 
The European League Against Rheumatism (EULAR) 
Sjögren’s Syndrome Disease Activity Index (ESSDAI) was con-
structed from a study consensus of the EULAR group and 
North-American for the study of PSS, and aims to quantify 
systemic disease activity. It comprises 12 areas: constitution-
al, lymphadenopathy, glandular, articular, cutaneous, pul-
monary, renal, muscular, peripheral nervous system, central 
nervous system, hematological, and biological. These areas 
are scored based on clinical parameters evaluated by the phy-
sician.15 
The transcultural adaptation of tools developed in another 
culture or language is not restricted to a simple translation of 
the original item. The process should contain a sequence of 
the following equivalence steps:16 conceptual and item equiv-
alence (whether domains, concepts, and items assess the 
same parameters in both languages ); semantic equivalence 
(whether words or phrases have the same meaning; com-
prising the following steps: translation, back-translation, dis-
cussion with experts, and pre-test); operational equivalence 
(whether the format, instructions, administration and mea-
surement methods are equivalent in both cultures); measure-
ment (testing the psychometric properties); and functional 
equivalence (whether the original tool and summarized ver-
sion are equivalent).
In measurement equivalence, the psychometric properties 
assessed are reproducibility (whether measures of individu-
als at different times and in different circumstances produce 
the same or similar results) and validity (whether the test is 
actually measuring what it intends to measure).5,17 
In preliminary studies of tool construction, ESSDAI was 
proven to be a tool with high content validity, good construct 
validity and reproducibility, with a clear and objective scor-
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ing system, good association of their domains with disease 
activity, and better responsiveness and accuracy to detect 
changes in the activity of the patients compared to previous 
tools.11,15,18-22
In addition to the need for validation of this tool, it is es-
sential that its properties are tested in several languages  and 
in different populations of patients with PSS. This allows for 
the performance of transcultural studies and comparisons 
between national and international studies, thus providing 
scientifi c communication between countries of different lan-
guages.23 Currently, the ESSDAI has been published only in the 
English language; this study aimed to perform its transcul-
tural adaptation into Brazilian Portuguese.
Method
This was a cross-sectional observational study approved by 
the Research Ethics Committee of the Centro de Ciências da 
Saúde of the Universidade Federal do Espírito Santo (UFES), 
in 2010, and developed at the Sjögren’s syndrome outpatient 
clinic of the Rheumatology Service of the Hospital Universi-
tário Cassiano Antonio de Moraes, in Vitória, state of Espírito 
Santo, Brazil.
The procedures to perform the transcultural adaptation of 
ESSDAI followed the methodology proposed by Herdman et 
al.,16 which covers six steps: conceptual, item, semantic, op-
erational, measurement, and functional equivalences.
Twenty patients were selected for the  semantic equiva-
lence, and 62 patients for the evaluation of measurement 
equivalence. Inclusion criteria were: diagnosis of PSS based 
on the European-American classifi cation criteria for Sjögren’s 
syndrome,24 age equal to or greater than 18 years, and sign-
ing of the informed consent. Patients with other concomitant 
autoimmune diseases were excluded. 
The sample was calculated based on the use of at least fi ve 
patients per domain of the tool,25 in a total of 62 patients, with 
57 patients from the Sjögren’s syndrome outpatient clinic of 
the Rheumatology Service of HUCAM, two from other teach-
ing hospitals, and three from private practices. Among the 115 
patients enrolled in the service, 30 did not meet the inclusion 
criteria and 28 were not found to participate in the interview.
The conceptual, item, semantic, and operational equiva-
lences of ESSDAI were verifi ed at the time of the translation 
and back-translation by a committee comprising a rheu-
matologist, a physical therapist specialized in Rheumatol-
ogy, both of whom had experience managing patients with 
PSS and were fl uent in English, and an English teacher. The 
translation of the ESSDAI was performed independently by 
two English teachers whose native language is Brazilian Por-
tuguese, and who were aware of the purpose of the study. At 
the back-translation, this version was submitted to transla-
tion into English by two other English teachers, whose native 
language is English, blinded to the original version and to the 
study objective. 
In the pretest, the consensus version in Portuguese was ap-
plied to 20 consecutive patients diagnosed with PSS by a rheu-
matologist experienced in the management of these patients.
In the measurement equivalence, the psychometric 
properties were compared to the original tool, according to 
Streiner and Norman5 and Kirshner and Guyatt17. The evalu-
ated properties were reliability (interobserver reproducibility) 
and construct validity. The 62 patients underwent medical 
consultation, and the Physician Global Assessment (PhGA), 
ESSDAI, Sjögren’s Systemic Clinical Activity Index (SCAI),18 
and Sjögren’s Syndrome Disease Activity Index (SSDAI)19 tools 
were completed on the same day by two independent rheu-
matologists (examiner A and B) experienced in the manage-
ment of patients with PSS who were blinded and  in separate 
rooms. The tools were scored from 0 to 10 for PhGA, 0 to 123 
for ESSDAI, 0 to 72 for SCAI, and 0 to 21 for SSDAI.15,18,19 
For construct validity, the ESSDAI was compared with the 
following tools: numerical PhGA, and SSDAI and SCAI trans-
lated into Brazilian Portuguese.26,27 Subsequently, the sample 
was divided into two groups (active and inactive) according 
to the onset or worsening of potentially reversible signs and 
symptoms of the disease in the past four weeks, as defi ned by 
a medical specialist.
The ESSDAI was also compared with the “intention to 
treat” on the day of medical assessment compared to the pre-
vious evaluation. Intention to treat was defi ned as a change in 
therapy, whether change in drug dosage, drug withdrawal, or 
inclusion of a new drug. The medications of interest were im-
munosuppressants, hydroxychloroquine, oral or intravenous 
corticosteroids, immunoglobulins, and biological agents. The 
sample was classifi ed into two groups: increase and non-in-
crease of therapy. 
The collected data were analyzed and processed with the 
Statistical Package for Social Sciences (SPSS), release 19.0. The 
intraclass correlation coeffi cient (ICC), Bland-Altman plots, 
and weighted kappa were used for interobserver reproduc-
ibility. Spearman’s coeffi cient was used for construct valid-
ity, when comparing ESSDAI with numerical PhGA, SCAI, and 
SSDAI.28 Mann-Whitney’s test was used to test ESSDAI in the 
comparison between the “active” and “inactive” groups and 
between the “increase in therapy” and “non-increase in ther-
apy” groups.28 A P-value ≤ 0.05 was considered to be statisti-
cally signifi cant in all analyses. 
Results
There were no differences between the versions in the two 
languages regarding the phases of item, conceptual, seman-
tic, and operational equivalences; and thus the fi nal consen-
sual Brazilian version was obtained.
Demographic characteristics and disease manifestations 
of the 62 patients are shown in Table 1. 
Regarding the study’s interobserver reproducibility, a 
strong and signifi cant intraclass correlation coeffi cient (0.898) 
was obtained between the two examiners when assessing the 
total ESSDAI score, showing high reproducibility. The analysis 
by the Bland-Altman plot (Fig. 1) presented a good interob-
server agreement of ESSDAI, with only three patients outside 
the standard deviation interval of ± 1.96 (outliers).  
Weighted kappa was used for the interobserver correla-
tion regarding the different domains of ESSDAI. There was no 
agreement in the lymphadenopathy domain; in the consti-
tutional domain, the agreement was low (kappa: 0.1-0.4); in 
the glandular and articular domains, it was moderate (kappa: 
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0.41-0.60); and in the cutaneous, respiratory, renal, peripheral 
nervous system, hematological, and biological domains there 
was good agreement (kappa: 0.61 to 0.8) (Table 2). The renal 
and cutaneous domains showed the highest agreement, 0.791 
and 0.792, respectively.
For construct validity, in comparison with numerical 
PhGA, a strong Spearman’s  coeffi cient of 0.832 (P < 0.000) was 
obtained; a moderate result was obtained with SSDAI (0.658, P 
< 0.000), and a weak result with SCAI (0.411, P = 0.001) - Table 3. 
Table 4 presents the mean and median of ESSDAI; in the 
active group, it was greater than in the inactive group by nom-
inal PhGA, and there was a statistically signifi cant difference 
between the groups (P = 0.000). The active group had the high-
est mean rank in the ESSDAI when compared to the inactive 
group. 
When comparing the ESSDAI according to the intention 
to treat between the groups, a statistically signifi cant differ-
ence was observed between the groups (P = 0.000) (Table 4). 
The group with increase in therapy had higher ESSDAI values 
when compared to the group with no increase in therapy.
Discussion
There were no differences in the interpretation and , since 
it is a tool with mostly clinical domains, which are technical 
and objective in nature, with clear language and good under-
standing by the physician. 
The demographic and clinical characteristics of the 62 
patients were similar to those found in other studies of PSS 
tools (SCAI, SSDAI) and cohorts of patients with a prevalence 
of women > 93%; mean age 47 to 59 years; long disease dura-
tion, with a mean of 7.2 years;15,18,19,22,29-33 and mean interval 
between symptom onset and diagnosis of fi ve years, which 
demonstrates a long delay in the diagnosis of this disease, 
previously reported by other authors.34 
There was a high prevalence of dryness, confi rmed by ob-
jective testing and high positivity of minor salivary gland bi-
opsy (90.3%), similar to other studies.15,18
One of the diffi culties of validation studies of PSS activity 
tools, such as the SCAI and SSDAI, is that most of the study 
patients had inactive or slightly active disease.15,18,19,29 The 
total ESSDAI score ranges from 0 to 123. In the Argentinean 
study of ESSDAI validation into Spanish, a mean ESSDAI score 
of 5 was observed (ranging from 3 to 9), as well as a mean 
PhGA of 1.0 (0.4 to 2.2), that is, a prevalence of patients with 
low disease activity and inactivity.29 Cohorts from different 
Table 1 – Characteristics and disease manifestations of 
62 patients with PSS. 
Characteristics n (%) or mean ± SD
Age (years) 49.4 ± 11.6
Female gender 62 (100)
Disease duration 7.2 ± 5.4
 Objective ocular dryness 48 (77.4)
 Objective oral dryness 53 (85.5)
 Lymphocytic sialadenitis ≥ one 
focus-score 
56 (90.3)
 Anti-Ro antibody 27 (43.6)
 Anti-La antibody 12 (19.4)
Positive antinuclear factor 48 (77.4)
Rheumatoid factor 14 (21.6)
Active disease by specialist 33 (53.2)
Numerical PhGA 1.82 ± 1.87
ESSDAI 4.95 ± 6.73
SSDAI 1.71 ± 1.89
SCAI 4.85 ± 3.00
Frequency of systemic manifestations 
Constitutional 6 (9.7)
Lymphadenopathy 1 (1.6)
Glandular 5 (8.1)
Articular 17 (27.4)
Cutaneous 3 (4.8)
Respiratory 9 (14.5)
Renal 5 (8.1)
Muscular 0
Peripheral nervous system 7 (11.3)
Central nervous system 0
Hematological 25 (40.3)
Biological 25 (40.3)
Fatigue 48 (77)
PSS, primary Sjögren’s syndrome; SD, standard deviation; PhGA, 
Physician Global Assessment; ESSDAI, EULAR Sjögren’s Syndrome 
Disease Activity Index; SCAI, Sjögren’s Systemic Clinical Activity 
Index; SSDAI, Sjögren’s Syndrome Disease Activity Index. 
Fig. 1 – Agreement between ESSDAI score measurements 
between two examiners using the Bland-Altman method.
Table 2 – Results of interobserver agreement per ESSDAI 
domain.
Domains Weighted kappa 
Constitutional 0.212a
Lymphadenopathy -0.016
Glandular 0.588a
Articular 0.450a
Cutaneous 0.792a
Respiratory 0.638a
Renal 0.791a
Muscular -
Peripheral nervous system 0.759a
Central nervous system -
Hematological 0.693a
Biological 0.693a
a Statistically signifi cant kappa, P <  0.05.
Mean between the two examiners
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countries where ESSDAI was applied showed a mean of: 4 (0 
to 43) in the English, 5.7 (0 to 29) in the French, 3.18 (0 to 29) 
in the Dutch, and 11.1 (0 to 37) in the Finnish cohort; 30,31,33,35 
all these samples showed patients with low disease activity. 
In the ESSDAI construction study, the mean total score was 
15.5 (2 to 47), with only 25% of patients with a score ≥ 13.15 
In the present study, 46.8% of the patients included had sys-
temic manifestations at the moment of inclusion, and 61.3% 
had already had a disease fl are. At the time of evaluation, ac-
tive disease was detected in 53.2% according to the nominal 
PhGA; however, there was a predominance of low activity, 
which was observed in 38.7% of patients. This low activity 
was confi rmed by the mean numerical PhGA score of 1.92 and 
the mean total ESSDAI score of 4.95 (0 to 39), with 11.3% of 
patients with a score ≥ 12, similar results to those of the Ar-
gentinean validation study.29
Disease activity in PSS is more diffi cult to detect than in 
other systemic rheumatic diseases, such as systemic lupus 
and rheumatoid arthritis, and the clinical course of PSS is 
usually more insidious.36 Furthermore, it can be observed that 
systemic manifestations are observed in only one-third of 
patients with PSS, which can hinder the inclusion of a large 
number of patients in the studies. One way to solve this prob-
lem would be to perform multicenter national or international 
studies, to attain a better composition of the research sample.
The study interobserver reproducibility was substantial be-
tween the two examiners (ICC = 0.898). In the Argentinean vali-
dation study, reproducibility was good, but lower, with an ICC 
= 0.67 (P = 0.06) for ESSDAI.29 Regarding other PSS activity tools, 
the SSDAI validation study did not assess reproducibility, and 
the SCAI study obtained a good correlation of 0.71.18,19 Although 
these results did not present a strong correlation (ICC > 0.8), 
they are still better than the reproducibility results of PhGA in 
PSS in the literature, which showed an ICC = 0.41.15 The disease 
assessment by the physician through PhGA is subject to con-
siderable variability, as it is greatly infl uenced by the patient’s 
symptoms such as fatigue and pain, which are subjective pa-
rameters that are diffi cult to measure and highly variable in 
such a polymorphic disease. This also justifi es the need for the 
validation of a more objective tool that includes systemic man-
ifestations, such as ESSDAI, to be used in different situations, 
by different physicians, whether experienced or not.
When analyzing the results of ESSDAI interobserver agree-
ment by the Bland-Altman method, a good agreement was 
obtained; however, the mean difference between examiners 
was 1.1. This indicates that there may have been a score over-
estimation by one examiner in relation to the other. Some hy-
potheses to explain this result are the difference in time of 
experience in the clinical management of PSS between the 
examiners and the absence of tool calibration between the 
two examiners.
There are no similar studies in the literature to compare 
whether an error variation of 1.1 between examiners for ESS-
DAI is clinically relevant or not. Furthermore, this tool does not 
have stratifi cation values  of its total score or an established 
cutoff to defi ne disease activity. After the cutoff value and the 
clinically important minimal difference are established by an 
international multicenter ESSDAI validation study that will 
soon be completed, the difference between examiners can be 
better interpreted regarding clinical relevance. 
The interobserver reproducibility per ESSDAI domain dem-
onstrates that the agreement was satisfactory in the six do-
mains, i.e., they had a large number of cases whose result was 
the same among examiners (weighted kappa between 0.61 
and 0.8). No other studies were found in the literature that 
performed this domain-by-domain comparison for PSS tools.
The two domains with regular agreement, the glandular 
and articular domains, contain subjective parameters that 
Table 3 – Descriptive measures and correlation of ESSDAI with other tools in PSS.
Variables Mean (±) Minimum Median Maximum Spearman’s coeffi cient P-value
ESSDAI 4.95 ± 6.73 0 3 39 --- ---
Numerical PhGA 1.82 ± 1.87 0 1 7 0.832 (P < 0.000)
SSDAI 1.71 ± 1.89 0 1 8 0.658 (P < 0.000)
SCAI 4.85 ± 3.00 1 4.5 16 0.411 (P = 0.001)
Scores of tools:  PhGA: 0-10 (Pincus et al., 2008); ESSDAI: 0-123  (Seror et al., 2010b); SSDAI: 0-21 (Vitali et al., 2007); SCAI: 0-72 (Bowman et al., 2007).
PSS, primary Sjögren’s syndrome; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; PhGA, Physician Global Assessment; SSDAI, 
Sjögren’s Syndrome Disease Activity Index; SCAI, Sjögren’s Systemic Clinical Activity Index.
Table 4 – Descriptive measures and Mann-Whitney’s test for ESSDAI in groups according to activity by nominal PhGA 
and intention to treat.
ESSDAI - Total score 
n Minimum value Maximum value Median Mean SD Mid posts P-valuea
Nominal PhGA
Inactive 29 0 7 0.00 1.21 1.68 17.14 0.000
Active 33 1 39 6.00 8.24 7.75 44.12
Intention to treat
Increase in therapy 11 5 39 10.00 13.18 11.12 52.05 0.000
No increase in 
therapy
51 0 15 2.00 3.18 3.53 27.07
ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; PhGA, Physician Global Assessment; SD, standard deviation. 
aMann-Whitney test.
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may have infl uenced the outcome. In the glandular domain, 
the distinction between mild or signifi cant increase in glandu-
lar, submandibular, and lacrimal volume is at the examiner’s 
discretion, which can generate an over- or underestimation 
from one examiner in relation to the other. In the articular 
domain, the item “arthralgia in hands, wrists, ankles, and feet 
accompanied by morning stiffness > 30 minutes” is a param-
eter answered by the patient, which can be a source of bias 
between examiners, as the patient may have other causes of 
associated joint pain, causing an examiner to score differ-
ently from the other.   
The sample showed a frequency of associated fi bromyal-
gia of 43.5% (n = 27) and patients with comorbidities were not 
excluded. Nevertheless, it is worth remembering that the tool 
itself asks not to take into account other causes of joint pain, 
such as osteoarthritis and fi bromyalgia,15 frequently found in 
individuals with PSS.  
Another factor that may have contributed to little or no 
agreement in some domains was the lack of training of the 
two examiners on individual items prior to the application 
or calibration. In some similar studies, the physicians were 
trained to score the tools to improve their reproducibility;18,37,38 
however, in order to simulate and adhere to daily clinical 
practice, the authors chose not to perform the calibration in 
this study. 
The ESSDAI tool is a formative model, in which the items 
themselves have no value, but rather are assembled together 
to constitute a fi nal construct.39 This construct, measured by 
the total score, should have adequate reliability and repro-
ducibility. When these items are evaluated individually, there 
may not be complete agreement, as examiners may disagree 
on an item and agree on others. What should be ultimately 
considered, thus, is the agreement of the tool’s total score.5 
The construct validity of ESSDAI with PhGA was good (co-
effi cient 0.83, P < 0.000), and slightly better than that found 
in the ESSDAI construction study (0.61, P < 0.001)15 and in the 
Argentinean validation study (0.79, P < 0.01).29 The validity of 
SSDAI with PhGA showed similar results (0.87, P < 0.0001).19 
The construct validity of ESSDAI with SSDAI was moderate, 
whereas it was weak with SCAI. This result can be explained 
in part by the limitations of the method, as the SCAI and SS-
DAI are not the gold standard for comparing validity data. 
They are transition tools that did not achieve good results in 
their psychometric properties, as they showed low content 
validity and reproducibility. Moreover, the SCAI has patient-
reported subjective items such as fatigue, morning stiffness, 
dyspnea, and Raynaud’s phenomenon, which may have con-
tributed to its poor correlation with ESSDAI. 
Any measure of validity that is performed  will show some 
associated error, and as a consequence, it should be expect-
ed that the correlation between tools of the same attribute 
should achieve a mean between 0.4 and 0.8. Any correlation 
lower than that suggests that the reliability of one or the oth-
er tool is unacceptably low, or that they are measuring dif-
ferent phenomena.5,24 Thus, the coeffi cient of 0.411 found for 
SCAI is within the minimally acceptable limit suggested by 
the literature.  
When evaluating validity between groups, ESSDAI was able 
to discriminate between active and inactive groups classifi ed 
by PhGA, and by intention to treat and therapeutic change by 
the expert physician, despite the low variability of patients 
and the sample size. A mean of 1.2 was obtained in the in-
active group and of 8.2 in the active group, with signifi cant 
difference (P < 0.05), i.e., higher values  of ESSDAI accompany 
higher values  of disease activity assessed by the physician, as 
well as greater use of immunosuppressive therapy. There are 
no other studies in the literature that used this type of evalu-
ation per groups for ESSDAI to compare these results.
Currently, ESSDAI has been applied to several European co-
horts,30,31,40,41 and the tendency of recommendations is to use it 
in practice and medical research, not alone, but together with 
other activity parameters such as the EULAR Sjogren’s Syn-
drome Patient Reported Index (ESSPRI) symptom question-
naire,42 objective tests of saliva (sialometry sialochemistry) 
and tears (ocular dryness score), and laboratory parameters of 
autoimmune infl ammation (measurement of cytokines, gam-
maglobulins, IgG, and β2 microglobulins).11,43 Its multicenter 
validation, which is in progress, as well as its translation into 
different languages,  are crucial to achieve a uniform scientifi c 
language in different countries and to compare studies, in or-
der to facilitate clinical research on PSS.
Conclusion
This study demonstrated that the use of ESSDAI in the evalu-
ated sample, which had demographic and clinical characteris-
tics similar to other populations from PSS activity index stud-
ies, showed a strong correlation with the overall assessment 
of activity scored by the physician and was able to discrimi-
nate active from inactive patients in the Brazilian setting. 
The authors conclude that the Brazilian Portuguese ver-
sion of ESSDAI was shown to be adaptable, reproducible, and 
valid for this language.
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Appendix – EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI).
Constitutional domain (3)
Please, be careful not to evaluate constitutional symptoms unrelated to the disease (such as fever of infectious origin, 
voluntary weight loss).
No activity Absence of the following symptoms:  0
Low activity Mild or intermittent fever (37.5°-38.5°C) / night sweats and/or involuntary weight loss of 5% to 10% of 
body weight  
 1
Moderate activity Severe fever (> 38.5°C) / night sweats and/or involuntary weight loss of > 10% of body weight  2
Lymphadenopathy domain (4)
No activity Absence of the following features:  0
Low activity Lymphadenopathy ≥ 1 cm in any nodal region or ≥ 2 cm in inguinal region  1
Moderate activity Lymphadenopathy ≥ 2 cm in any region or ≥ 3 cm in inguinal region, and/or splenomegaly (clinically 
palpable or assessed by imaging) 
 2
High activity Current malignant B-cell proliferative disorder  3
Glandular domain (2)
Please be careful not to evaluate increased glandular volume unrelated to the disease (such as lithiasis or infection).
No activity Absence of glandular swelling  0
Low activity Small glandular swelling with: 
• enlarged parotid (≤ 3 cm), or discrete submandibular or lachrymal swellinga
 1
Moderate activity Major glandular swelling with: 
• enlarged parotid (> 3 cm), or important submandibular or lachrymal swellinga
 2
Articular domain (2)
Please be careful not to evaluate joint involvement unrelated to the disease, such as osteoarthritis.
No activity Absence of currently active articular involvement  0
Low activity Arthralgia in hands, wrists, ankles and feet accompanied by morning stiffness (> 30 min)  1
Moderate  activity 1 to 5 (of 28 total count) synovitisb  2
High activity ≥ 6 (of 28 total count) synovitisb  3
Cutaneous domain (3)
Please be careful not to evaluate as “No activity” old and stable lesions that are more related to the damage (sequelae) than 
to the disease activity or cutaneous involvement unrelated to the disease.
No activity Absence of currently active cutaneous involvement  0
Low activity Erythema multiforme  1
Moderate  activity Limited cutaneous vasculitis, including urticarial vasculitisc, purpura limited to feet and ankle, or 
subacute cutaneous lupus 
 2
High activity Diffuse cutaneous vasculitis, including urticarial vasculitisc, diffuse purpura, or ulcers related to 
vasculitis 
 3
(continued on next page)
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Appendix – EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) (continued).
Respiratory domain (5)
Please be careful not to evaluate as “No activity” stable and old lesions more related to the damage (sequelae) than with 
disease activity or respiratory involvement unrelated to disease (ex. cigarette smoking).
No activity Absence of currently active pulmonary involvement  0
Low activity Persistent cough or bronchial involvement with no radiographic abnormalities on common X-ray or 
evidence of interstitial lung disease at plain x-ray or high resolution computed tomography (HRCT) with: 
• No breathlessness, and
• normal lung function test.
 1
Moderate  activity Moderately active pulmonary involvement, such as interstitial lung disease shown by HRCT with 
• shortness of breath on exertion (NHYAd II) or abnormal lung function tests restricted to: 70% > DLCOe  
≥ 40% or 80% > FVCf ≥ 60% 
 2
High activity Highly active pulmonary involvement, such as interstitial lung disease shown by HRCT with:
• shortness of breath on small exertion or rest (NHYAd III, IV) or abnormal lung function tests: DLCOe< 
40% or FVCf< 60% 
 3
Renal domain (5)
Please be careful not to evaluate as “No activity” stable and old lesions that are more related to the damage (sequelae) than 
with disease activity and renal involvement unrelated to the disease.
If a biopsy is performed, please classify the activity based primarily on histological characteristics.
No activity Absence of currently active renal involvement with:
• proteinuria < 0.5 g/d, no hematuria, no leukocyturia, no acidosis, or 
• long-lasting stable proteinuria due to damage/sequelae
 0
Low activity Evidence of specifi c renal activity involvement, limited to:
• tubular acidosis without renal failure, or 
• glomerular involvement 
- with proteinuria (between 0.5 and 1 g/dL), and
- without hematuria or renal failure (GFRg ≥ 60 mL/min) 
 1
Moderate  activity Moderate renal activity:
• tubular acidosis with  renal failure (GFRg < 60 mL/min), or
• glomerular involvement:
           -  with proteinuria  between 1 and 1.5 g/d, and
           -  no hematuria or renal failure (GFRg ≥ 60 mL/min) 
• histological evidence:
-  glomerulonephritis, and/or 
- important interstitial lymphoid infi ltrate
 2
High activity High renal activity:
• glomerular involvement:
- proteinuria > 1.5 g/dL, and/or
- hematuria, and/or
- renal failure (GFRg< 60 mL/min), or
• histological evidence of:
- proliferative glomerulonephritis, or
- cryoglobulinemia related to renal involvement
 3
Muscular domain (6)
Please be careful not to evaluate muscle involvement unrelated to the disease, such as weakness due to corticosteroids.
No activity Absence of currently active muscle involvement  0
Low activity Mild active myositis shown by abnormal EMG or biopsy with:
• no weakness and altered creatine kinase (N < CK ≤ 2N)
 1
Moderate  activity Moderately active myositis proven by abnormal EMG or biopsy with:
• weakness (maximal defi cit of 4/5), or elevated creatine kinase (2N < CK ≤ 4N),
 2
High activity Highly active myositis shown by abnormal EMG or biopsy with:
• weakness (defi cit ≤ 3/5) or elevated creatine kinase  (> 4N)
 3
(continued on next page)
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Appendix – EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) (continued).
Peripheral nervous system (PNS) domain (5)
Please be careful not to evaluate as “No activity” stable and old lesions that are more related to the damage (sequelae) than 
to the activity or involvement of the peripheral nervous system unrelated to the disease.
No activity Absence of currently active PNS involvement  0
Low activity Evidence of mild active peripheral nervous system involvement, such as:
• axonal peripheral polyneuropathy diagnosed by NCS/EMG, or
• trigeminal (V) neuralgia
 1
Moderate  activity Evidence of moderately active involvement of the peripheral nervous system, such as:
• motor and sensory axonal neuropathy diagnosed by NCS / EMG, without motor defi cit, or
• pure sensory neuropathy with presence of cryoglobulinemic vasculitis or 
•  ganglionopathyh with symptoms restricted to moderate ataxia, or
• chronic infl ammatory demyelinating polyneuropathy (CIDP)i with moderate functional disability 
(without motor defi cit or moderate ataxia), or
• peripheral cranial nerve involvement - except trigeminal nerve (V)
 2
High activity Evidence of highly active involvement of the peripheral nervous system, such as:
• motor and sensory axonal neuropathy diagnosed by NCS/EMG with motor defi cit ≤ 3/5, or 
• peripheral nerve involvement attributed to vasculitis (mononeuritis multiplex), or 
• severe ataxia attributed to ganglionopathy h or
• CIDPi with severe functional disability: motor defi cit ≤ 3/5 or severe ataxia
 3
Central nervous system (CNS) domain (5)
Please be careful not to evaluate as “No activity” stable and old lesions that are more related to the damage (sequelae) than 
to the disease activity or involvement of the central nervous system unrelated to the disease.
No activity Absence of currently active CNS involvement  0
Moderate  activity Moderately active CNS manifestations, such as:
• involvement of cranial nerve or central origin, or
• optical neuritis, or
• multiple sclerosis-like syndrome with symptoms restricted to pure sensory impairment or proven 
cognitive impairment 
 1
High activity Highly active CNS manifestations, such as:
• cerebral vasculitis with cerebrovascular accident or transient ischemic attack
• seizures, or 
• transverse myelitis, or
• lymphocytic meningitis, or
• multiple sclerosis-like syndrome with motor defi cit.
 2
Hematological domain (2)
Please note: taking into account anemia, neutropenia and thrombocytopenia, only autoimmune cytopenia should be 
considered; do not evaluate cytopenia that is unrelated to the disease (such as vitamin or iron defi ciency, and drug-induced 
cytopenia, e.g., lymphocytopenia associated with cyclophosphamide).
No activity Absence of auto-immune cytopenia  0
Low activity Cytopenia of auto-immune origin with:
• neutropeniaj (1,000 < neutrophils < 1,500/mm3), and/or anemiak (10 <  Hb  < 12 g/dL), or thrombocytopenial 
(100,000 <  platelets  < 150,000/mm3), or lymphopenia (500 < lymphocytes < 1,000/mm3)
 1
Moderate  activity Cytopenia of auto-immune origin with:
• neutropeniaj (500 ≤ neutrophils  ≤  1,000/mm3), or anemiak (8 ≤  Hb  ≤ 10 g/dL), or thrombocytopenial 
(50,000 ≤ platelets ≤ 100,000/mm3), or lymphopenia (≤ 500/mm3)
 2
High activity Cytopenia of auto-immune origin with:
• neutropeniaj (neutrophils < 500/mm3), or anemiak (Hb < 8 g/dL) or thrombocytopenial (platelets  < 
50,000/mm3)
 3
(continued on next page)
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Appendix – EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) (continued).
Biological domain (1)
No activity Absence of any of the following biological alterations:  0
Low activity • Clonal component and/or hypocomplementemia (low C4 or C3 or CH50) or hypergammaglobulinemia 
or high IgG level between 1,600 and 2,000 mg/dL
 1
Moderate  activity • Presence of cryoglobulinemia and/or hypergammaglobulinemia or high IgG level > 2,000 mg/dL, or 
recentm onset of hypogammaglobulinemia or recent decrease of IgG level (< 500 mg/dL)
 2
N, normal (reference value); EMG, electromyography.
a The distinction between discrete or major swelling of submandibular or lacrimal gland volume is at the physician’s discretion.
b The 28 articulations included in the calculation of the Disease Activity Score 28are shoulders, elbows, wrists, metacarpophalangeal, proximal 
interphalangeal and knee joints.
c Limited cutaneous vasculitis involves < 18% of body surface area (BSA), diffuse cutaneous vasculitis involves > 18% of BSA. BSA is defi ned using 
the rule of nines (used to assess the extent of burns) as shown below: palm (excluding fi ngers) = 1% BSA; each lower limb = 18%; each upper 
limb = 9%; trunk (frontal) = 18% BSA; trunk (dorsal) = 18% BSA. 
 For the diagnosis of interstitial lung disease, High Resolution Computed Tomography or plain radiography are necessary and must have been 
performed within the last two years.
d NYHA (New York Heart Association functional classifi cation).
e DLCO (Lung Diffusion Capacity Testing).
f FVC (Forced Vital Capacity).
g Glomerular fi ltration rate (GFR) calculated through the Modifi cation of Diet in Renal Disease (MDRD) formula.
h Pure sensory disability with ataxia and diffuse disability or abolition of sensory potential in nerve conduction study (NCS) 
i Polyradiculoneuropathy with suggestive clinical symptoms (sensorimotor defi cit in the four limbs, proximal motor defi cit, generalized 
arefl exia, early sensory symptoms affecting the upper limbs, and/or associated with cranial nerve involvement), increased protein level and/
or abnormal NCS (prolonged motor distal latency, reduced nerve conduction velocity, prolonged F wave latency, conduction blockade and/or 
temporal dispersion).
j Neutropenia of unknown etiology.
k Anemia with positive Coombs’ test and increased reticulocyte count
l Thrombocytopenia of peripheral origin with no other known etiology, or in case of diffi cult to perform identifi cation of anti-platelet 
autoantibodies and/or presence of megakaryocytes in bone marrow aspirate and/or associated autoimmune anemia.
m In the last six months.
